Slide 1: Uscom Annual General Meeting
USCOM ANNUAL GENERAL MEETING 29th October 2020 Record growth with blue sky ahead. ASX: UCM Prof. Rob Phillips WELCOME
Slide 2: Agenda
AGENDA “Record growth with blue sky ahead” 01 03 02 FY2021 04 05 Presentation FY2020 Strategy Proceedings Questions Financial, Operational, Results Products and Uscom More Products, More Resolutions Investors China Global Growth Markets and More Sales
Slide 3: Chairman's Presentation
01 Chairman’s Presentation Financial, Operational, Products and Uscom China “Record growth with blue sky ahead.”
Slide 4: Uscom has delivered record growth in a challenging commercial world
“ Uscom has delivered record growth in a challenging commercial world. Medical technology is a cornerstone of health and investment, and Uscom continues to execute a targeted global strategy of growth and expansion. While the future is uncertain, China, Uscom’s major market, is rebounding, as Uscom
Slide 5: Uscom Mission
USCOM MISSION Who We Are Our Vision Our Drive Uscom are the experts in circulation Uscom isinnovative, delivering the expert in circulation practice changing To improve clinical care in AA commercial commercial ambition ambition to become to become a leaderain disease. non-invasive deliveringcardiov
Slide 6: Uscom Apex Technologies
USCOM APEX TECHNOLOGIES USCOM 1A Uscom SpiroSonic Uscom BP+ VENTITEST A non-invasive advanced Uscom digital ultrasonic spirometers Provides central and brachial All ventilators require hemodynamic monitor that are high fidelity, digital, pulmonary blood pressure and pulse intermittent testing and me
Slide 7: Uscom Boards
USCOM BOARDS Prof Rob Phillips Mr Christian Bernecker Mr Brett Crowley Mr Meng Xianhui EXECUTIVE CHAIRMAN NON-EXECUTIVE NON-EXECUTIVE NON-EXECUTIVE In December the Board welcomed Mr Meng Xianhui as a new non-executive Director. Mr Meng is an experienced medical technology executive with experience i
Slide 8: Uscom People
USCOM PEOPLE Rob Phillips Nick Schicht Teresa Guo Lucy Lu Lebron Wei Denise Pater Rik Denicke George Ferenczi Nancy Wang Scarlett Zhang Curt Grosse Szabolcs Reichhardt Richard Scott Zsofia Kertesz Crystal Lin Daniel Gizella Susanna Sun Andrea Marosan 37 employees 4 continents Antonio Ferrario Szabo
Slide 9: FY2020 Results
02 FY2020 Results Global Growth “Record growth with blue sky ahead.”
Slide 10: Annual Results: Cash Receipts
2020: UCM Cash Receipts ANNUAL RESULTS $5.00 $4.60 ASX:UCM ↑ 36% $4.00 Record Cash Receipts and $3.50 $3.39 Sales $2.94 $2.90 $3.00 Growth Trend Continues $M AUD Cash Receipts $4.6M up 36% $2.04 $2.00 8yr CAGR = 23% PA $1.38 Cash on hand $1.92M $1.01 $1.00 $0.86 $0.00 2012 2013 2014 2015 2
Slide 11: Annual Results
2020: UCM Annual Results ↑ 36% ANNUAL RESULTS 5.00 4.6 4.00 ↑ 29% ASX:UCM 3.65 3.39 3.00 2.84 Record results Cash receipts up 36% 2.00 Sales up 29% $M AUD FY 19 ↑ $2.07M FY 20 Net cash flow up $2.07M 1.00 0.78 ↑ $0.04M Cash on hand $1.92M 0.00 Debt free Profit Net Cash Sales Cash Flow Re
Slide 12: H2 Results
2020: UCM H2 Results H2 RESULTS FY19 FY20 3.5 ↑ 83% ASX:UCM 3 ↑ 57% 3.02 Cash receipts $3.02M up 83% 2.8 2.5 Sales revenue $2.80M up 57% 2 1.78 1.64 Net cash flow up $1.47M 1.5 ↑ $1.47M Profit up $0.78M $M AUD 1 ↑ $0.78M Profitable and cash flow positive 0.5 0.5 0.14 0 Profit Net Cash Flow
Slide 13: 2020: Regional and Product Sales
2020: REGIONAL AND PRODUCT SALES China is the major Uscom market, and USCOM 1A the lead product. This will change as regulatory approvals are received for BP+ and SpiroSonic devices, particularly in China
Slide 14: Global Reach
GLOBAL REACH • London • Beijing • Budapest • LA Operations Sydney Singapore • Singapore Beijing Budapest Offices Auckland • Sydney London • Auckland LA HEDGED for CURRENCY and POLITIC RISK
Slide 15: Growth Capital
GROWTH CAPITAL MANAGEMENT AND LEAD INVESTORS FUND GROWTH CAPITAL $1.05m growth capital Build new USCOM 1A, BP+ and SpiroSonic devices Support new marketing initiatives in Europe and China Finalise the costs of China and US regulatory approvals Four subscribers bought additional ~7% of UCM Chairman a
Slide 16: Uscom China
USCOM CHINA China is the major Uscom market China is rebounding Uscom China is growing rapidly Teresa Guo is GM of Uscom China Appointed Head of Global Operations USCOM 1A the lead product, with BP+ and SpiroSonic devices approaching
Slide 17: COVID-19 (Sepsis)
COVID-19 (SEPSIS) 1. USCOM 1A recommended by SCCM for Pediatric Sepsis International Guidelines from US, UK, Europe, Canada, S America, India, Australia 51 Authors, 25% of authors are USCOM users or advocates 2. USCOM 1A recommended by PRC Govt to treat Severe COVID Recommended by Chinese National H
Slide 18: Regulatory Progress
REGULATORY PROGRESS NMPA USCOM 1A approved for 5 years SpiroSonic and BP+ progressing VENTITEST – notice to market prior to sales CE USCOM approved BP+ approved with revision in process SpiroSonic AIR – nearing issue VENTITEST – self notification prior to sales FDA USCOM 1A approved BP+ approved wit
Slide 19: Regulatory: Why it takes so long and costs so much
REGULATORY 18 Test For a small change in component reports (following 18 tests….) Why it takes so long and costs so much…… Documentation for a component update of BP+ 14 Reports 18 Test reports (following 18 tests….) 14 reports 13 Submissions 13 Submissions And why it’s valuable..…… Uscom – The Meas
Slide 20: New Patents 2020
NEW PATENTS 2020 Two new global PCT applications lodged Patent Cooperation Treaty (PCT) provides 18 months of global patent protection, prior to complete patent approval Improved hypertension diagnosis and treatment Ultrasonic testing and calibration of ventilators Thermometric normalization of Bloo
Slide 21: SpiroSonic AIR - Released
SPIROSONIC AIR - RELEASED Acute and chronic recovery phases of COVID-19 monitoring of pulmonary fibrosis, asthma and COPD 17% of all patients with severe COVID have restrictive lung disease after 3 months. It is unclear what happens next or how to treat them…… COVID-19 spirometry for home monitoring
Slide 22: BP+ & BP+ Reporter Released
BP+ & BP+REPORTER RELEASED BP+ with BP+ Reporter Precision Module Hardware – Software - Report BP+ Report Revolutionising diagnosis and treatment of hypertension and vascular health
Slide 23: BP+ New Standards
BP+ NEW STANDARDS The new BP+ acquires three high fidelity waveforms to understand cardiac and vascular function Competitor (Prev Gold Standard) Revolutionising hypertension H I G H F I D E L I T Y WAV E F O R M S Specialised products New standards of monitoring Blood Pressure and hypertension
Slide 24: VENTITEST-S Software
VENTITEST-S VENTITEST Software VENTITEST V E N T I T E S T- S S o f t w a r e For testing, archiving, analysis, display and reporting of ventilator performance
Slide 25: 2020: Branding and Marketing
2020: BRANDING AND MARKETING Uscom China Koala marketing logos Adult Maternal Health Paediatrics Neonates
Slide 26: 2020: New Distribution
2020: NEW DISTRIBUTION China – Beijing HQ for Uscom China Expanded distribution network – more and better distributors Current growth mostly from USCOM 1A – single product New products for NMPA approval over 6-12 months Predicted strong 12 month growth prior to new product approvals SE Asia – Ne
Slide 27: 2020: Milestones
2020: MILESTONES Uscom record sales and growth for Uscom First profitable and cash flow positive half Restructured Distribution - China, Europe and US COVID-19 role endorsed across China, Europe and the US Release of new SpiroSonic AIR and BP+ and BP+ Reporter VENTITEST and VENTITEST-S r
Slide 28: FY2021 Strategy
03 FY2021 Strategy More Products, More Markets and More Sales “Record growth with blue sky ahead.”
Slide 29: FY2021 Priorities
VENTITEST — Uscom ventilator calibration EE BP+ and SpiroSonic approvals due for China and US B Europe and US up-grading and increasing infectious disease centres New European and US distribution models Uscom China growing - numbers and quality of distributors * China economy rebounding — boom marke
Slide 30: New Uscom Blue Sky eHealth Ecosystem
Uscom Blue Sky eHealth New Uscom Blue Sky eHealth Ecosystem Data and AI Uscom Blue Sky eHealth Ecosystem new product new services Integrated new revenue Connecting Uscom devices Services and subscription to patients, clinicians and the cloud Blue Sky Uscom eHealth Ecosystem Software Clinical feedbac
Slide 31: Blue Sky eHealth Ecosystem: Progress Achieved
Blue Sky Uscom Blue Sky eHealth Uscom eHealth Ecosystem New Uscom Blue Sky eHealth Ecosystem Leading the way we manage chronic and infectious diseases Progress already achieved: - ~10 years experience in digital eHealth - $10M invested in digital health platform research from current cash flows - Wo
Slide 32: 2021: Risks
2021: RISKS The Pandemic – Widespread, unpredictable and uncertain future The US Trade War – The US trade wars and targeting of successful Chinese businesses may continue, however Uscom is confident in the opportunity of our China presence as China rebounds quickly Unpredictable global markets
Slide 33: 2021: Q1 Results
2021: Q1 RESULTS ASX:UCM ↑ 83% ↑ 413% Sales up 413% Cash receipts up 75% Net cash flow up $0.57M Profit up $1.03M ↑ $1.03M Increased cash on hand ↑ $0.57M Profitable and cash flow positive
Slide 34: Conclusion
“Record growth with blue sky ahead.” CONCLUSION “ Uscom continues to deliver record growth with real Blue Sky ahead New products, new distribution, recovering global markets, and the new Blue Sky eHealth Ecosystem will fuel our growth Uscom has created the digital cardiovascular and pulmonary sensor
Slide 35: Thank You
USCOM ANNUAL GENERAL MEETING 29th October 2020 Record growth with blue sky ahead. ASX: UCM Prof. Rob Phillips THANK YOU